Clinical trial • Phase III • Endocrinology
NNC0487-0111 (NN9490-8152) for Obesity
Phase III trial of NNC0487-0111 (NN9490-8152) for Obesity. Low-calorie diet; Placebo (details on dose/schedule not specified)-controlled. 120 participants.
Overview
- Trial Therapeutic Area
- Endocrinology
- Trial Disease
- Obesity
- Trial Stage
- Phase III
Key dates
- Initial CTIS Submission Date
- 23-01-2026
- First CTIS Authorization Date
- 11-05-2026
Trial design
Low-calorie diet; Placebo (details on dose/schedule not specified)-controlled Phase III trial across 2 sites in Denmark, Netherlands.
- Comparator
- Low-calorie diet; Placebo (details on dose/schedule not specified)
- Target Sample Size
- 120
Eligibility
Recruits 120 Vulnerable populations not selected; no specific consent or assent handling described in the provided record..
- Vulnerable Population
- Vulnerable populations not selected; no specific consent or assent handling described in the provided record.
Recruitment
- Planned Sample Size
- 120
- Recruitment Window Months
- 30
Geography
- Total Number Of Sites
- 2
- Total Number Of Participants
- 120
Denmark
- Earliest CTIS Part Ii Submission Date
- 08-05-2026
- Latest Decision Or Authorization Date
- 11-05-2026
- Processing Time Days
- 3
- Number Of Sites
- 1
- Number Of Participants
- 60
Sites
- Site Name
- Region Midtjylland
- Contact Person Name
- Nikolaj Rittig
- Contact Person Email
- nikolaj.rittig@clin.au.dk
Netherlands
- Earliest CTIS Part Ii Submission Date
- 06-05-2026
- Latest Decision Or Authorization Date
- 12-05-2026
- Processing Time Days
- 6
- Number Of Sites
- 1
- Number Of Participants
- 60
Sites
- Site Name
- Universiteit Maastricht
- Contact Person Name
- Gijs Goossens
- Contact Person Email
- G.Goossens@maastrichtuniversity.nl
Sponsor
Primary sponsor
- Full Name
- Novo Nordisk A/S
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- Denmark
Investigational products
- Investigational Product Name
- NNC0487-0111 (NN9490-8152)
Related trials
Other published trials that may interest you.
- TIRZEPATIDE for Obesity
- RO7795068 for Obesity
- L-PHENYLALANYL-2-METHYLALANYL-L-ALFA-GLUTAMYLGLYCYL-L-THREONYL-L-PHENYLALANYL-L-THREONYL-L-SERYL-L-ALFA-ASPARTYL-L-VALYL-L-SERYL-L-LYSYL-L-GLUTAMINYL-L-LEUCYL-L-ALFA-GLUTAMYL-L-ALFA-GLUTAMYL-L-LYSYL-L-ARGINYL-L-VALYL-L-ARGINYL-L-ALFA-GLUTAMYL-L-PHENYLALANYL-L-ISOLEUCYL-L-ALFA-GLUTAMYL-L-TRYPTOPHYL-L-LEUCYL-L-LYSYL-L-GLUTAMINYLGLYCYLGLYCYL-L-PROLYL-L-SERYL-L-SERYLGLYCYL-L-LYSYL-L-PROLYL-L-PROLYL-L-PROLYLGLYCYL-L-LYSYL-N6-[N-(19-CARBOXY-1-OXONONADECYL)-L-GAMMA-GLUTAMYL]-L-LYSINE for Obesity
- cagrilintide for Obesity
- ZENAGAMTIDE for Obesity